17 April 2025 - If approved, Eylea HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated for all other anti-VEGF therapies.
Regeneron Pharmaceuticals today announced that the US FDA has accepted for priority review the supplemental biologics license application for Eylea HD (aflibercept) Injection 8 mg.